David Nierengarten
Stock Analyst at Wedbush
(4.28)
# 384
Out of 5,129 analysts
208
Total ratings
52.51%
Success rate
15.79%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVB Nuvation Bio | Reiterates: Outperform | $11 | $5.56 | +97.84% | 12 | Feb 10, 2026 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $4.53 | +142.83% | 5 | Jan 30, 2026 | |
| COGT Cogent Biosciences | Reiterates: Outperform | $55 | $36.90 | +49.05% | 4 | Jan 21, 2026 | |
| IMNM Immunome | Reiterates: Outperform | $31 | $24.80 | +25.00% | 7 | Jan 15, 2026 | |
| NVCR NovoCure | Reiterates: Neutral | $18 | $10.25 | +75.61% | 9 | Jan 15, 2026 | |
| ARGX argenx SE | Reiterates: Outperform | $1,000 | $825.85 | +21.09% | 24 | Jan 14, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $48 → $50 | $44.59 | +12.13% | 5 | Jan 13, 2026 | |
| BCAX Bicara Therapeutics | Reiterates: Outperform | $30 | $14.65 | +104.78% | 3 | Jan 13, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $20 | $10.38 | +92.68% | 9 | Jan 13, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Reiterates: Outperform | $25 | $10.67 | +134.30% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $7 | $11.64 | -39.86% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 → $7 | $1.09 | +545.16% | 16 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $110 | $75.22 | +46.24% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $115 | $101.65 | +13.13% | 6 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4 | $3.98 | +0.50% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $11.88 | +118.86% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $7.02 | +213.39% | 3 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $13.17 | -39.26% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $20 | $15.65 | +27.80% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $48.77 | -17.98% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $64.95 | +38.57% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $47.06 | -0.13% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $32.98 | +21.29% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $32.71 | +37.59% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $0.97 | +935.63% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $3.90 | +361.54% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.33 | +260.36% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $26.48 | +115.30% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $2.72 | +18,282.35% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $6.40 | +837.50% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $7.80 | +143.59% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $23.50 | +219.15% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.13 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.66 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.72 | - | 3 | Nov 20, 2017 |
Nuvation Bio
Feb 10, 2026
Reiterates: Outperform
Price Target: $11
Current: $5.56
Upside: +97.84%
Perspective Therapeutics
Jan 30, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.53
Upside: +142.83%
Cogent Biosciences
Jan 21, 2026
Reiterates: Outperform
Price Target: $55
Current: $36.90
Upside: +49.05%
Immunome
Jan 15, 2026
Reiterates: Outperform
Price Target: $31
Current: $24.80
Upside: +25.00%
NovoCure
Jan 15, 2026
Reiterates: Neutral
Price Target: $18
Current: $10.25
Upside: +75.61%
argenx SE
Jan 14, 2026
Reiterates: Outperform
Price Target: $1,000
Current: $825.85
Upside: +21.09%
Kiniksa Pharmaceuticals International,
Jan 13, 2026
Maintains: Outperform
Price Target: $48 → $50
Current: $44.59
Upside: +12.13%
Bicara Therapeutics
Jan 13, 2026
Reiterates: Outperform
Price Target: $30
Current: $14.65
Upside: +104.78%
ORIC Pharmaceuticals
Jan 13, 2026
Reiterates: Outperform
Price Target: $20
Current: $10.38
Upside: +92.68%
BridgeBio Oncology Therapeutics
Dec 11, 2025
Reiterates: Outperform
Price Target: $25
Current: $10.67
Upside: +134.30%
Nov 7, 2025
Maintains: Neutral
Price Target: $9 → $7
Current: $11.64
Upside: -39.86%
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.09
Upside: +545.16%
Oct 17, 2025
Maintains: Outperform
Price Target: $90 → $110
Current: $75.22
Upside: +46.24%
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $101.65
Upside: +13.13%
Sep 8, 2025
Initiates: Outperform
Price Target: $4
Current: $3.98
Upside: +0.50%
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $11.88
Upside: +118.86%
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $7.02
Upside: +213.39%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $13.17
Upside: -39.26%
Mar 14, 2025
Downgrades: Neutral
Price Target: $80 → $20
Current: $15.65
Upside: +27.80%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $48.77
Upside: -17.98%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $64.95
Upside: +38.57%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $47.06
Upside: -0.13%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $32.98
Upside: +21.29%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $32.71
Upside: +37.59%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $0.97
Upside: +935.63%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $3.90
Upside: +361.54%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.33
Upside: +260.36%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $26.48
Upside: +115.30%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $2.72
Upside: +18,282.35%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $6.40
Upside: +837.50%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $7.80
Upside: +143.59%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $23.50
Upside: +219.15%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.13
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.66
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $8.72
Upside: -